Short Interest in OncoCyte (OCX) Rises By 5.9%

OncoCyte (NYSEAMERICAN:OCX) saw a significant growth in short interest during the month of March. As of March 29th, there was short interest totalling 854,481 shares, a growth of 5.9% from the March 15th total of 807,018 shares. Approximately 10.2% of the shares of the company are sold short. Based on an average daily volume of 251,899 shares, the days-to-cover ratio is currently 3.4 days.

Shares of OCX stock opened at $2.25 on Friday. OncoCyte has a 1 year low of $1.10 and a 1 year high of $7.85.

OncoCyte (NYSEAMERICAN:OCX) last issued its quarterly earnings results on Monday, April 2nd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.13).

Several equities research analysts recently issued reports on OCX shares. Janney Montgomery Scott cut OncoCyte from a “buy” rating to a “neutral” rating in a research note on Wednesday, March 21st. Zacks Investment Research cut OncoCyte from a “buy” rating to a “hold” rating in a research note on Friday, March 30th.

In other news, major shareholder Broadwood Partners, L.P. bought 3,968,254 shares of the firm’s stock in a transaction dated Wednesday, March 28th. The shares were bought at an average price of $1.26 per share, with a total value of $5,000,000.04. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

An institutional investor recently raised its position in OncoCyte stock. BlackRock Inc. boosted its holdings in shares of OncoCyte (NYSEAMERICAN:OCX) by 9.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 207,173 shares of the biotechnology company’s stock after purchasing an additional 17,204 shares during the period. BlackRock Inc. owned about 0.66% of OncoCyte worth $964,000 at the end of the most recent quarter.

ILLEGAL ACTIVITY NOTICE: This story was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at

OncoCyte Company Profile

OncoCyte Corporation focuses on the discovery, development, and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using proprietary sets of genetic and protein markers expressed in various types of cancer.

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with's FREE daily email newsletter.

Leave a Reply